Founded in 2014 in Seattle, Washington, Oisin develops DNA-directed gene therapies designed to selectively eliminate senescent or diseased cells. Its lead platform uses Suicide Gene Therapy™, which employs inducible promoters to activate cell-killing genes only in harmful cells. The company aims to rejuvenate tissues by reducing chronic inflammation and cellular dysfunction. (oisinbio.com)...